These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24393552)

  • 1. The role of xenobiotic transporters in ophthalmic drug delivery.
    Chemuturi N; Yanez JA
    J Pharm Pharm Sci; 2013; 16(5):683-707. PubMed ID: 24393552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive insight on ocular pharmacokinetics.
    Agrahari V; Mandal A; Agrahari V; Trinh HM; Joseph M; Ray A; Hadji H; Mitra R; Pal D; Mitra AK
    Drug Deliv Transl Res; 2016 Dec; 6(6):735-754. PubMed ID: 27798766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, activity and pharmacokinetic impact of ocular transporters.
    Vellonen KS; Hellinen L; Mannermaa E; Ruponen M; Urtti A; Kidron H
    Adv Drug Deliv Rev; 2018 Feb; 126():3-22. PubMed ID: 29248478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies.
    Dey S; Anand BS; Patel J; Mitra AK
    Expert Opin Biol Ther; 2003 Feb; 3(1):23-44. PubMed ID: 12718729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of membrane transporters and metabolizing enzymes in ocular drug delivery.
    Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
    Curr Drug Metab; 2014; 15(7):680-93. PubMed ID: 25255873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
    Babizhayev MA
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
    Attar M; Shen J; Ling KH; Tang-Liu D
    Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
    Bu HZ; Gukasyan HJ; Goulet L; Lou XJ; Xiang C; Koudriakova T
    Curr Drug Metab; 2007 Feb; 8(2):91-107. PubMed ID: 17305490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ways to improve ocular bioavailability for topical applications].
    Sirbat D; Marchal-Heussler L; Hoffman M; Maincent P
    J Fr Ophtalmol; 2000 May; 23(5):505-9; quiz 523. PubMed ID: 10844314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of metabolism in ocular drug delivery.
    Duvvuri S; Majumdar S; Mitra AK
    Curr Drug Metab; 2004 Dec; 5(6):507-15. PubMed ID: 15578944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics.
    Mannermaa E; Vellonen KS; Urtti A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1136-63. PubMed ID: 17081648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic model for ocular drug delivery.
    Tojo K
    Chem Pharm Bull (Tokyo); 2004 Nov; 52(11):1290-4. PubMed ID: 15516748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?
    Argikar UA; Dumouchel JL; Kramlinger VM; Cirello AL; Gunduz M; Dunne CE; Sohal B
    J Pharm Sci; 2017 Sep; 106(9):2276-2281. PubMed ID: 28322939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters.
    Jordán J; Ruíz-Moreno JM
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1181-92. PubMed ID: 23647131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR; Cason MM; Womble SW; Li G; Chastain JE
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of ocular drug penetration.
    Sasaki H; Yamamura K; Mukai T; Nishida K; Nakamura J; Nakashima M; Ichikawa M
    Crit Rev Ther Drug Carrier Syst; 1999; 16(1):85-146. PubMed ID: 10099899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes.
    Loch C; Zakelj S; Kristl A; Nagel S; Guthoff R; Weitschies W; Seidlitz A
    Eur J Pharm Sci; 2012 Aug; 47(1):131-8. PubMed ID: 22659372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.